Sign in

Robert M. Davis

Chairman, CEO, and President at Merck & Co.
Board
Since December 2022
Age
58 years
Tenure
Joined Merck & Co., Inc. in 2014 and has held multiple leadership roles, progressing from CFO and Executive Vice President roles to serving as CEO and ultimately assuming the roles of Chairman, CEO, and President in December 2022.

Also at Merck & Co.

BDL
Betty D. Larson
EVP and Chief Human Resources Officer
CL
Caroline Litchfield
EVP and Chief Financial Officer
CG
Chirfi Guindo
Chief Marketing Officer

About

Robert M. Davis is 58 years old as of February 1, 2025, and has established himself as a key leader at Merck & Co., Inc. Not much personal background is available beyond his age, and no details regarding his education have been provided.

After joining Merck in 2014, he embarked on a rapid career progression. He held pivotal roles including Chief Financial Officer and Executive Vice President, and later advanced to become CEO and President from July 2021 until December 2022. In December 2022, he took on the additional responsibilities as Chairman, reflecting his significant contributions across the company.

Beyond his roles at Merck, he has also demonstrated leadership in other capacities, notably serving on the Board of Directors at Duke Energy since 2018, where he contributes to critical governance matters. His experience from previous positions at Baxter International further supports his comprehensive understanding of the corporate and financial environments, rounding out his professional profile.

$MRK Performance Under Robert M. Davis

Past Roles

OrganizationRoleDate RangeDetails
Merck & Co., Inc. Chief Executive Officer and President July 2021 – December 2022 Former position before current role
Merck & Co., Inc. Executive Vice President, Global Services, and Chief Financial Officer April 2016 – July 2021 Held prior to appointment as Chairman, CEO & President
Merck & Co., Inc. Chief Financial Officer and Executive Vice President 2014 – 2016 Previous senior finance leadership role
Baxter International, Inc. Corporate Vice President and President, Medical Products 2010 – 2014 Held leadership in medical products
Baxter International, Inc. Corporate Vice President and Chief Financial Officer 2006 – 2010 Oversaw financial operations
Baxter International, Inc. Corporate Vice President and Treasurer 2004 – 2006 Managed treasury functions

External Roles

Organization Role Date Range Details
Duke Energy Board of Directors N/A Chair of the Finance & Risk Management Committee; Member of the Corporate Governance Committee

Fixed Compensation

Data from  FY 2023
Component NameAmountPayment ScheduleAdditional Details
Base Salary$1,603,091 AnnuallyFixed base salary
Financial/Tax Counseling & Tax Preparation$10,000 As IncurredPart of All Other Compensation
Company Aircraft$91,519 As IncurredPart of All Other Compensation
Company Car and Driver$15,224 As IncurredPart of All Other Compensation
Home Security (Installation/Maintenance)$11,824 As IncurredPart of All Other Compensation
Savings Plan Company Match and Credits$257,580 As IncurredPart of All Other Compensation

Performance Compensation

Data from  FY 2023

Annual Incentive (Cash-Based)

MetricDetails
Base Salary$1,615,000
Target Incentive (150%)$2,422,500
Company Scorecard Result148%
Final Award$3,585,300
Vesting ScheduleImmediate payout based on 2023 performance
Evaluation Period2023 (annual)

Long-Term Incentive (LTI)

ComponentGrant DateGrant Date Fair ValueGrant Date Stock PriceTarget/Maximum SharesPerformance MetricsVesting Schedule
Performance Share Units (PSUs)March 31, 2023$9,997,585 N/ATarget: 88,824 shares; Max: 177,648 shares 50% Three-Year Cumulative EPS & 50% Relative TSR; EPS thresholds: Threshold: $19.53 (25%), Target: $21.46 (100%), Stretch: $24.04 (200%) Vest at end of three-year performance period
Stock OptionsMay 2, 2023$4,050,000 $117.89 N/AValue realized if stock price exceeds grant price; no additional performance thresholds provided Vest in three equal annual installments

Note: Pro-rata Annual Cash Incentive details are integrated into the Annual Incentive component above. All performance payouts are determined based on the Company Scorecard and related pre-determined metrics.

Interviews

Merck CEO Robert Davis goes one-on-one with Jim Cramer thumbnail

Merck CEO Robert Davis goes one-on-one with Jim Cramer

CNBC Television
8:01 min
Jan 15, 2025
Merck CEO on Winrevair Approval, Obesity Drug, Health Costs thumbnail

Merck CEO on Winrevair Approval, Obesity Drug, Health Costs

Bloomberg Television
5:53 min
Mar 28, 2024
Merck CEO Robert Davis on Q3 results: Our portfolio sets us up for a good finish to the year thumbnail

Merck CEO Robert Davis on Q3 results: Our portfolio sets us up for a good finish to the year

CNBC Television
6:04 min
Oct 31, 2024
Merck CEO Rob Davis on Q2 results: We continue to see phenomenal growth thumbnail

Merck CEO Rob Davis on Q2 results: We continue to see phenomenal growth

CNBC Television
6:07 min
Aug 1, 2023